UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 20, 2026

TSCAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-40603**	**82-5282075**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
830 Winter Street **Waltham, Massachusetts** (Address of principal executive offices)		**02451** (Zip Code)

Registrant's telephone number, including area code 857 399-9500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Voting Common Stock, par value $0.0001 per share	TCRX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 20, 2026, TScan Therapeutics, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting") virtually at 8:30 a.m. Eastern Time for the purposes of considering and voting upon the proposals below. As of the record date of October 16, 2026, there were a total of 63,502,657 shares of the Company's voting common stock, par value $0.0001 per share (the "Voting Common Stock"), issued and outstanding and entitled to vote at the Special Meeting. There were 43,545,428 shares of Voting Common Stock present virtually or represented by proxy at the Special Meeting, or approximately 68.57% of the shares issued and outstanding and entitled to vote at the Special Meeting, representing a quorum. Capitalized terms used, but not defined herein, shall have the meaning set forth in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on October 26, 2026.

Proposal No. 1 - Approval of the Reverse Stock Split Proposal

The stockholders of the Company approved an amendment to the Company's Amended and Restated Certificate of Incorporation to combine outstanding shares of the Company's common stock, par value $0.0001 per share, consisting of Voting Common Stock and non-voting common stock, into a lesser number of outstanding shares by a ratio of not less than one-for-two and not more than one-for-fifty, with the exact ratio to be set within this range by the Company's board of directors in its sole discretion (the "Reverse Stock Split Proposal"). The results of the stockholders' vote with respect to the Reverse Stock Split Proposal were as follows:

Votes For	Votes Against	Abstain	Broker Non-Votes
41,922,357	1,610,640	12,431	0

Proposal No. 2 - Adjournment Proposal

The Adjournment Proposal was not tallied because the Reverse Stock Split Proposal was approved.

No other matters were submitted to or voted on by the Company's stockholders at the Special Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TScan Therapeutics, Inc.

Date: November 23, 2026

By: /s/ Gavin MacBeath, Ph.D.
Gavin MacBeath, Ph.D.
Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)